Monday, July 20, 2026

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 39

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 39 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

  1. Botulinum toxin type A

    Hospital Authority, Hong Kong

    Obesity

    phase 3 small molecule active

    1 trial
  2. Eloralintide

    Eli Lilly and Company

    Obesity

    phase 3 small molecule active

    1 trial
  3. I8F-MC-GPIX

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial
  4. J1I-MC-GZBP

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial
  5. K9531-3107

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial
  6. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials
  7. NN8022-4392

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial
  8. NN9838-7749

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial
  9. NN9838-7859

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial
  10. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 3 small molecule active

    1 trial
  11. lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 3 small molecule terminated

    1 trial
  12. ARO-INHBE

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial
  13. BC45538

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial
  14. EP-005

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial
  15. ISIS-FGFR4RX

    IONIS PHARMACEUTICALS INC

    Obesity

    phase 2 small molecule completed

    1 trial
  16. KAI-7535

    Kailera Therapeutics

    Obesity

    phase 2 small molecule active

    2 trials
  17. Naltrexone hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 2 small molecule active

    1 trial
  18. Pramlintide+Metreleptin

    Takeda

    Obesity

    phase 2 small molecule terminated

    1 trial
  19. TTP435

    vTv Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial
  20. Tirzepatide

    Regeneron UK Limited

    Obesity

    phase 2 small molecule completed

    1 trial
  21. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Obesity

    phase 2 small molecule completed

    1 trial
  22. aleniglipron or placebo

    Structure Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial
  23. MBX 4291

    MBX Biosciences

    Obesity

    phase 1 small molecule active

    1 trial
  24. Placebo

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 1 small molecule completed

    1 trial
  25. RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

    Rani Therapeutics Holdings

    Obesity

    phase 1 other active

    1 trial
  26. ANGELO

    The George Institute

    Obesity

    approved small molecule active

    1 trial
  27. Berberine plus lifestyle intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obesity

    approved small molecule completed

    1 trial
  28. Candesartan and Hydrochlorothiazide

    Takeda

    Obesity

    approved small molecule completed

    1 trial
  29. ESOMEPRAZOLE, ESOMEPRAZOLE

    Fondazione Telethon ETS

    obesity

    approved small molecule active

    1 trial
  30. EXPAREL

    Pacira Ireland Limited

    Obesity

    approved small molecule completed

    1 trial
  31. Intravenous Ibuprofen

    CUMBERLAND PHARMACEUTICALS INC

    Obesity

    approved small molecule completed

    1 trial
  32. NN9536-7752

    NovoThirteen

    Obesity

    approved small molecule active

    1 trial
  33. Pioglitazone

    Takeda

    Obesity

    approved small molecule completed

    1 trial
  34. Semaglutide

    United Therapeutics Europe Ltd

    Obesity

    approved small molecule terminated

    1 trial
  35. Semaglutide B 3.0 mg/ml PDS290

    Disc Medicine

    obesity

    approved small molecule active

    1 trial
  36. Simvastatin

    Hospital Authority, Hong Kong

    Obesity

    approved small molecule active

    1 trial
  37. Iron Isomaltoside injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obesity

    small molecule active

    1 trial
  38. Oral supplementation of vitamin D

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obesity

    other completed

    1 trial
  39. Phentermine

    Takeda

    Obesity

    small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

39 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.